Bronchiectasis
Conditions
Keywords
HFCWO, Bronchiectasis, SmartVest
Brief summary
The primary objective is to compare the patient's baseline QoL prior to HFCWO use against the patient's QoL at various study timepoints over a one-year period of HFCWO use.
Detailed description
This study will use a prospective interventional comparative study design using the patient's quality of life (QoL) as the primary study endpoint to determine HFCWO affect. The study will compare the patient's QoL baseline (established at enrollment prior to HFCWO treatment) to the QoL measured at various timepoints (enrollment, 2 months, 6 months and 12 months) over a one-year period whilst receiving HFCWO treatment. In addition, a baseline for the secondary endpoints will established at enrollment for comparison to measurements taken at various timepoints over a one-year period whilst receiving HFCWO treatment. The patient's medical records will be used to establish prior histories of exacerbation rates for comparison to exacerbation rates experienced after one year of HFCWO treatment. Patients will serve as their own control.
Interventions
DEVICESmartVest Airway Clearance System
Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
Sponsors
University of Alabama at Birmingham
Electromed, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 18 years of age or older 2. Previous diagnosis of bronchiectasis confirmed by HRCT within the last 6 months 3. Patients must have at least 6 months of medical records related to bronchiectasis 4. Patients must be stable and currently on a standard of care regimen for bronchiectasis such as hypertonic saline and/or PEP 5. Patients with 1 or more exacerbations within the last 12 months 6. Previous and existing productive cough 7. No previous HFCWO use
Exclusion criteria
1. Patients who are known to have cystic fibrosis 2. Patients who are known to have primary ciliary dyskinesia (PCD) 3. Patients with chronic obstructive pulmonary disease (COPD) without bronchiectasis 4. Patients breathing via an artificial airway 5. Severe bronchospasm based on exam or history 6. Any comorbidity(ies) or contraindications that would normally complicate tolerating HFCWO treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life (QoL): Quality of Life-Bronchiectasis (QOL-B) questionnaire | 1 year | The primary endpoint is the subject's quality of life (QoL) using the Quality of Life-Bronchiectasis (QOL-B) questionnaire as the measurement tool. QoL measured at enrollment (baseline) will be compared to QoL measured at 2 months, 6 months and 1 year. The previously validated questionnaire is titled Quality of Life Questionnaire - Bronchiectasis. The Likert style questionnaire asks the subject to subjectively rank their symptoms using a 4 scale base ranging from a lot of difficulty to no difficulty and always to never. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Measurements | 1 year | 1. Exacerbation rates a. Pre HFCWO exacerbation rates will be established by review of the patient's medical records. Post HFCWO will recorded at 2 months, 6 months and 1 year. 2. Exacerbation frequency 1. The time to the subject's next exacerbation will be recorded for comparison pre to post HFCWO 2. Lung function (FEV1, FVC, FEF25-75) measured by standard spirometry 3. Sputum production measured by using the Breathlessness, Cough and Sputum Scale (BCSS) questionnaire 4. Patient adherence to HFCWO treatment measured by SmartVest Connect wireless feature 5. Six-minute walk test measured using American Thoracic Society standard test guidelines/protocol 6. Radiographic changes compare patient's original high-resolution computerized tomography (HRCT) taken to initially |
Countries
United States
Outcome results
None listed